Monitor the DiamiR merger progress closely, as failure could severely impact the stock. Watch for future Nasdaq compliance issues and the outcome of the ongoing litigation. The company's survival depends on successful financing or merger completion.
Price Chart
Executive Summary
Aptorum Group Ltd (APM) is a clinical-stage biopharmaceutical company with no revenue, significant losses, and an auditor's going concern warning. It is attempting a merger with DiamiR, which would give existing shareholders only 30% of the combined company. The company has minimal employees, ongoing litigation, and faces substantial risks including Nasdaq delisting and potential trading prohibitions due to auditor inspection issues.
Key Facts
- Company reported a net loss of $1.38M for 2025 and has an accumulated deficit of $73.8M.
- Auditor has expressed substantial doubt about the company's ability to continue as a going concern.
- Proposed merger with DiamiR would result in existing Aptorum shareholders owning only 30% of the combined company.
- Company has only 2 full-time employees and relies heavily on consultants.
- Faced a lawsuit alleging RICO violations, fraud, and securities law breaches, with a motion to dismiss filed.
- Received a Nasdaq minimum bid price deficiency notice but regained compliance.
- Controlled by CEO Ian Huen who owns 87% of voting power through Class B shares.
- Company has ceased clinic operations and suspended non-lead R&D projects to focus on the merger.
Financial Impact
The company has $3.5M in cash but reported $1.8M in net cash used in operations for 2025. The proposed merger would significantly dilute existing shareholders.
Risk Factors
- Going concern risk due to insufficient cash and recurring losses
- Merger failure could lead to delisting and inability to raise capital
- Litigation could result in significant costs and damages
- Potential trading prohibition if PCAOB cannot inspect auditors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-035484 |
| Document: ea028161201ex12-2.htm | 0001213900-26-035484 |
| Document: ea028161201ex12-1.htm | 0001213900-26-035484 |
| Document: ea028161201ex13-1.htm | 0001213900-26-035484 |
| Document: ea028161201ex15-1.htm | 0001213900-26-035484 |
| Document: 0001213900-26-035484-index-headers.html | 0001213900-26-035484 |
| Document: 0001213900-26-035484-index.html | 0001213900-26-035484 |
| Document: 0001213900-26-035484.txt | 0001213900-26-035484 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 18d ago | 8-K | — | awaiting T+1 | — | — |
Oct 9, 2026 18d ago | 424B5 | — | awaiting T+1 | — | — |
Jul 20, 2026 14w ago | 8-K | $8.83 $9.54 | ▲ +8.04% | ▲ +7.21% | — |
Jul 16, 2026 14w ago | Press Release | $0.6924 $0.7000 | ▲ +1.10% | ▲ +2.09% | — |
Jun 10, 2026 19w ago | 6-K | $0.9038 $0.8900 | ▼ −1.53% | ▼ −3.23% | — |
Jun 4, 2026 20w ago | EFFECT | $1.09 $1.01 | ▼ −7.34% | ▼ −4.74% | — |
May 14, 2026 23w ago | 6-K | $0.8230 $0.8570 | ▼ −4.13% | ▼ −4.19% | — |
Mar 27, 2026 30w ago | 20-F | $0.8380 $0.7960 | ▲ +5.01% | ▲ +7.90% | — |
Mar 6, 2026 33w ago | Press Release | $0.8000 $0.7930 | ▲ +0.88% | ▲ +0.69% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers